Dynamic treatment for early-stage triple-negative breast cancer
November 2nd 2021Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.
Recruitment to Phase 2 Trial Examining PDS0101 Triplet in HPV Cancers Temporarily Suspended
November 1st 2021The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute–led phase 2 trial, which is evaluating a novel triplet combination comprised of PDS0101 and 2 immunomodulating agents in patients with advanced human papillomavirus cancers.
CoopERA Results Show Benefits of Giredestrant in ER+/HER2– Early Breast Cancer
October 29th 2021Sara Hurvitz, MD, discusses the coopERA study and how these data, along with findings from other clinical trials, could lead to significant changes in treatment for patients with ER-positive/HER2-negative breast cancer.
Supreme Court to review Texas abortion law
October 28th 2021The U.S. Supreme Court has agreed to review Texas’ controversial abortion ban on Nov. 1. However, they refused to block the law during the examination process, during which they will decide whether the Department of Justice has the right to sue to block the law.
Community-based activity programs benefit underserved breast cancer survivors
October 27th 2021Medically underserved and minority breast cancer survivors experienced improved outcomes and quality of life after participating in community-based physical activity programs, according to recent study results.
Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer
October 25th 2021The immuno-oncology company Agenus has made the decision to withdraw its biologic license application for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.
Menstrual cycle length changes linked to increased risk of atherosclerosis
October 19th 2021In an analysis of SWAN data, investigators found changes in menstrual cycle length within the 5 years preceding a woman's final menstrual period was associated with changes in carotid intima-media thickness and brachial-ankle pulse wave velocity.
Analytics for advanced care success
October 18th 2021Data analytics allows providers to gain insights from performance management measures and metrics that hold the clues to financial viability under risk-based and pay-for-performance contracts. By embracing advanced analytics, hospitals and health systems can accelerate their path to value.